Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mediwound ( (MDWD) ) just unveiled an update.
On January 12, 2026, MediWound issued a corporate and financial update ahead of the J.P. Morgan Healthcare Conference, detailing clinical, operational and financial milestones achieved through 2025 and its outlook for the coming years. The company reported that its global Phase III VALUE trial of EscharEx in venous leg ulcers is progressing, with interim assessment and full enrollment of 216 patients across roughly 40 U.S. and European sites expected by year-end 2026, and plans to extend the program into diabetic foot ulcers via a Phase II trial and into pressure ulcers via an investigator-initiated study during 2026, supported by collaborations with several major wound care companies. MediWound also confirmed that its expanded NexoBrid manufacturing facility is now fully operational, boosting production capacity sixfold ahead of anticipated regulatory approvals in 2026, and said it expects discussions among Vericel, BARDA and U.S. authorities on a potential multi-year NexoBrid program, including stockpiling and new formulations, to move forward in early 2026. Financially, the company reported $17 million in 2025 revenue and a $54 million year-end 2025 cash position with no debt, and updated its revenue guidance to $24–26 million for 2026, $32–35 million for 2027, and $50–55 million for 2028, implying a step-up in long-term growth driven by NexoBrid capacity expansion, continued BARDA and U.S. Department of Defense support, and an expected initial revenue contribution from EscharEx later in the decade.
The most recent analyst rating on (MDWD) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.
Spark’s Take on MDWD Stock
According to Spark, TipRanks’ AI Analyst, MDWD is a Neutral.
Mediwound’s overall stock score is primarily impacted by its challenging financial performance, characterized by ongoing losses and negative cash flows. Technical analysis indicates a bearish trend, further weighing down the score. Valuation metrics are unfavorable due to negative earnings and the absence of dividends. While the earnings call provided some positive insights into future growth potential, these are overshadowed by current financial and operational challenges.
To see Spark’s full report on MDWD stock, click here.
More about Mediwound
MediWound Ltd. (Nasdaq: MDWD) is an Israel-based global biotechnology company specializing in enzymatic, non-surgical therapies for tissue repair. Its FDA-approved biologic NexoBrid is used for enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan and additional international markets, while its late-stage pipeline product EscharEx is an investigational therapy for debridement of chronic wounds that targets becoming a new standard of care in wound management.
Average Trading Volume: 76,077
Technical Sentiment Signal: Buy
Current Market Cap: $247.5M
Learn more about MDWD stock on TipRanks’ Stock Analysis page.